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electrohydrodynamic atomization technique in order to develop ﬁxed dose combined formulations incorporat-
ing paracetamol and indomethacin as model drugs. The developed drug delivery systems offered successful
co-encapsulation of paracetamol and indomethacin with high drug encapsulation efﬁciencies of 54% and 69%
for paracetamol and indomethacin, respectively. The developed formulationswere further characterisedwith re-
spect to their morphology, drug release proﬁle and possible interactions. In comparison to the release rate of the
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demonstrates a versatile polymeric platformwheremultiple drug encapsulation and co-delivery ismadepossible
by utilizing co-axial electrohydrodynamic atomization. The proposed system offered high processing yield of 60–
70%, as a single-step platform for preparation of ﬁxed dose formulations for oral drug delivery, particularly in ge-
riatric therapy.





Polypharmacy, ﬁxed dose combination1. Introduction
Fixed dose combination drugs, also known as FDCs, are essentially
two or more active pharmaceutical ingredients formulated in a single
dosage form [1]. These formulations are relatively common for nearlyhe).
. This is an open access article underall therapeutic areas and are available for different routes of administra-
tion including oral, parenteral and inhalation; amongwhich the oral de-
livery route is the most common [2]. Fixed dose combination products
are of key importance in treating numerous types of diseases such as
cardiovascular, HIV/AIDS, malaria and tuberculosis where multiple
therapies are required [3–6]. Different pharmacological mechanisms
can be introduced into one single dosing unit offered by FDC products
[7]. This often presents synergistic value in therapeutic outcomes [8]the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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dividual drugs. The potential for drug abuse can be minimised by use of
combined drugs, where onewould diminish the unintended side effects
of the other [9]. Moreover, incorporation of both short acting and long
acting active pharmaceutical ingredients enables coverage of an extend-
ed period for therapeutic effect. These formulations also enable combi-
nation of drugs where one improves the safety and/or tolerability of
the other. In addition, FDC products reduce manufacturing costs. None-
theless, design and process development of FDC formulations are chal-
lenging compared with single entity products [10,11]. Various factors
complicate the development of these formulations. These are the size
of the prepared tablet of the FDC product, disproportionate drug dose
combination and different aqueous solubility [1].
Electrohydrodynamic atomization (EDHA) has been utilized to assist
encapsulation of both hydrophilic and hydrophobic active pharmaceuti-
cal ingredients with reported high encapsulation efﬁciency and fabrica-
tion yield [12–14]. This technique also offers control over particle size
and morphology and hence the release proﬁle and bioavailability of the
incorporated active ingredients in the body [15]. Solvent evaporation in
the process also negates the need for post processing of the developed
particles [16]. Furthermore, EHDA results in preparation of polymeric
particles with narrow size distributions that are extremely attractive for
pharmaceutical applications [17]. In a study by Bohr et al. [18], EHDA
was used for preparation of amorphous formulations of low water solu-
ble drug, where monodispersed polymeric drug delivery systems were
developed and offered an enhanced release proﬁle and dissolution rate
of celecoxib. EHDA has also been used for preparation of targeted drug
release, where the site-speciﬁc delivery of an active pharmaceutical in-
gredient is desirable [19]. In a recent study by Jia et al. [20] nanoﬁbers
were developed for delivery of indomethacin and mebeverine using co-
axial electrospinning for targeted treatment of bowel disease and colon
cancer. Careful selection of processing materials and ﬁne-tuning of the
co-axial composition system can introduce different mechanisms of
release and complex structural features onto polymeric drug delivery
systems. In a recent study [21] ethyl cellulose functional nano-ﬁbers
were produced and zero-order release of ketoprofen was achieved.
Indomethacin is a light-sensitive nonsteroidal anti-inﬂammatory
drug (NSAID), which is used as a prescription medication to relieve
pain and inﬂammatory conditions. It has poor water-solubility and is
also classiﬁed as a highly permeable drug [22]. Indomethacin in an
amorphous solid state is found to be the most soluble of all solid
forms [23]. Indomethacin was electrosprayed onto reduced and atmo-
spheric pressure in a study by Nyström et al. [24] and it was found
that the reduced particle size gave rise to higher surface area to volume
ratio. In addition to that, the resultant amorphous state of the indo-
methacin particles enhanced its solubility [24]. Paracetamol is an anal-
gesic used for reducing mild to moderate body pain. It also acts as an
antipyretic which helps to decrease body temperature [25]. It is
completely adsorbed from the intestinal tract and metabolized by the
liver. At high concentrations it can result in hepatic injury [26]. Attempts
have beenmade to prepare oral controlled release formulations of para-
cetamol to enable slow release in a controlledmanner into the gastroin-
testinal tract. With this objective, in a recent study, mucoadhesive
microspheres of xanthan gum and guar were developed incorporating
paracetamol [27]. Endo et al. [28] has reported development of gel for-
mulation for the oral delivery of paracetamol with high bioavailability
of 90% in rabbit. In-situ gelling formulations comprising gellan gum
and sodium alginate have also been developed for oral delivery ofTable 1
Compositions of the double layer polymeric systems used in this work.
Polymer system Inner solution
S1 2% w/w PEG in MeOH
S2 4% w/w PEG in MeOH
S3 6% w/w PEG in MeOHaqueous paracetamol solution. For this purpose, functionalised depots
were developed and were able to introduce controlled release paracet-
amol for 6 h, with similar bioavailability to those of commercial suspen-
sions [29].
Co-axial electrohydrodynamic atomization was used in this work in
order to prepare drug delivery systems,wherebymodel drugs of different
aqueous solubility, paracetamol (PCM) and indomethacin (INDO), were
embedded in polymeric particles. For this purpose, poly (lactic-co-
glycolic acid) (PLGA) and polyethylene glycol (PEG) were used [30,31],
as they are both biocompatible, non-toxic polymers that are approved
by FDA and excessively used for biopharmaceutical applications [32–34].
Themain objective of thisworkwas to co-encapsulate the two drugs
into polymeric matrices with the aim to increase the dissolution rate of
indomethacin and achieving controlled release of paracetamol, using
co-axial electrohydrodynamic atomization. On the basis of successful
application of this technique to incorporate multiple active pharmaceu-
tical ingredients, this work would present a potential platform for de-
velopment of ﬁxed dose combination formulations that are attracting
increasing attention in the area of geriatric and cancer therapy.
The proposed system is based on the hypothesis that the placement
of the non-water soluble drug in the outer layer would result in posi-
tioning of the drug at the outermost surface, hence, having higher sur-
face area to volume ratio, in addition to minimising diffusion distance
when compared to the hydrophilic drug in the inner layer. Inclusion of
the water soluble paracetamol was based on the fact that the outer
PLGA layer would protect it from undergoing burst release and so
prolonging the release period. If the polymer combinationwas reversed,
using PEG in the outer surface would consequently result in burst re-
lease of the incorporated drug. The aforementioned reasoning was the
logic in using PEG in the inner layer and PLGA in the outer layer, also
demonstrating that the system is adoptable for variant polymer/drug
composition, proving it to be a viable platform for further enhancement
of development of the customized polymeric drug delivery system as
demanded by FDC developments.
2. Experimental details
2.1. Materials
PLGA copolymer (50:50) Resomer RG503H of average molecular
weight 33,000 g/mol was obtained from Boehringer Ingelheim
Germany. PEG of molecular weight 8000 g/mol, dimethylcarbonate
and methanol, indomethacin (≥99.0% purity) and paracetamol
(≥99.0% purity) were supplied by Sigma-Aldrich (Poole, UK). All of the
above were used as received.
2.2. Solution preparation
4% w/w, 6%w/w and 8%w/w PLGA solution wasmade by dissolving
appropriate amount of PLGA in dimethylcarbonate (DMC) followed by
mechanical stirring to ensure complete dissolution of the polymer. To
prepare the drug incorporated solution 0.4% w/w indomethacin (solu-
bility in water 0.937 mg/l [35]) in DMC was then added to the 4% w/w
PLGA solution followed by further stirring to facilitate thorough dissolu-
tion of both the polymer and themodel drug under ambient conditions,
20 °C and 40–60% relative humidity. 2% w/w, 4% w/w and 6% w/w PEG
solutions was prepared by dissolving PEG in methanol and was stirred
until complete dissolution of PEG. To prepare the drug incorporatedOuter solution Mean particle size (μm)
4% w/w PLGA in DMC 8.06 ± 0.84
6% w/w PLGA in DMC 6.74 ± 0.70
8% w/w PLGA in DMC 6.40 ± 0.85
Table 2
Properties of the solutions used in this work.
Solution Surface tension (mN/m) Viscosity (mPa s) Electrical conductivity (μS/cm)
2% w/w PEG in MeOH 22.8 ± 0.30 0.93 ± 0.05 22.3 ± 0.45
4% w/w PEG in MeOH 23.1 ± 0.61 0.99 ± 0.05 24.9 ± 0.88
6% w/w PEG in MeOH 22.87 ± 0.15 1.19 ± 0.04 29.5 ± 0.25
4% w/w PLGA in DMC 25.7 ± 0.16 1.97 ± 0.19 0.01 ± 0
6% w/w PLGA in DMC 27.9 ± 0.7 2.63 ± 0.09 0.03 ± 0
8% w/w PLGA in DMC 27.7 ± 0.17 4.59 ± 0.08 0.03 ± 0.005
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[26]) was then added to the prepared 2% w/w PEG solution and stirred
to ensure complete dissolution of both the polymer and themodel drug
at the ambient conditions, 20 °C and 40–60% relative humidity. These
ambient conditions were kept in all our experiments in this work.
Details of polymeric systems and the developed formulations are
shown in Tables 1–4, respectively.2.3. Electrohydrodynamic atomization
In the co-axial EHDA set-up used in this work, two stainless steel
needles in concentric conﬁguration (Stainless Tube & Needle Co Ltd.,
Tamworth, UK) were connected to a high power voltage supply
(Glassman Europe Ltd., Tadley, UK) as shown in Fig. 1. Both needles
were infused simultaneouslywith the polymeric solutions. The external
and internal diameters of the outer needle were 2.03 mmand 1.52mm,
respectively; those of the inner needle were 1.07 mm and 0.69 mm, re-
spectively. The needles were connected to plastic syringes (10 ml) (BD
Plastic™, VWR, Lutterworth, UK), by means of silicone tubing (inner di-
ameter of 1.0 mm, Sterilin Ltd., Newport, UK): the syringes were placed
onto precision syringe pumps (PHD 4400, Harvard Apparatus,
Edenbridge, UK).
The applied voltage and ﬂow rates were varied based on the poly-
meric solution properties in order to achieve a stable cone jet, resulting
in formation of particles with desired characteristics. The working dis-
tance of 150 mm (distance between needle tip and the collector) was
ﬁxed for all of the experiments in order to conﬁrm that the applied elec-
tric ﬁeld strength was changed in proportion to the applied voltage
values. The polymeric particles were then collected onto glass slides or
a stainless steel platform connected to the ground electrode for charac-
terization and drug release measurements, respectively. The formation
of the jet and droplets was observed using a LEICA DMS300 camera. Ex-
periments were done at ambient conditions. The yield of the process
was determined by measuring the amount of collected particles for a
given amount of time and comparing to that of the theoretical amount
of particle collection for that speciﬁed period as a measure to examine
the processing yield of the proposed system at ambient conditions.
Processing Yield %ð Þ
¼ actual weighed amount of microparticles=theoretical weight amount of microparticlesð Þ
100%
ð1ÞTable 3
The compositions of the developed formulations. PCMP: paracetamol particles, INDOP:
indomethacin particles, PCMINDOP: paracetamol-indomethacin particles.
Formulation Inner solution Outer solution
PCMP 2% w/w PEG, 0.2% w/w
Paracetamol in MeOH
4% w/w PLGA in DMC
INDOP 2% w/w PEG in MeOH 4% w/w PLGA, 0.4% w/w
Indomethacin in DMC
PCMINDOP 2%/w PEG, 0.2% w/w
Paracetamol in MeOH
4% w/w PLGA, 0.4% w/w
Indomethacin in DMC2.4. Solution characterization
The density, electrical conductivity, surface tension and viscosity of
the prepared polymeric solutions used for the development of the for-
mulations were measured. A standard density bottle (DIN ISO 3507-
Gay-Lussac) was used for density measurement. A U-tube viscometer
(size E, VWR, Lutterworth, UK) was used for viscosity assessments. Sur-
face tension measurements were made with Kruss tensiometer (Model
DSA100, Kruss GmbH, Hamburg, Germany) adopting the Wilhelmy's
plate method. A conductivity probe (Jenway 3540 pH/conductivity
meter) was used to measure the electrical conductivity of the prepared
solutions. These characteristics are presented in Table 3. All the experi-
ments were run in triplicate at ambient conditions with calibrated
equipment, at ambient conditions.
2.5. Particle characterization
2.5.1. Optical and scanning electron microscopy
Particles that were collected on glass slides were analysed primarily
using an opticalmicroscope (Nikon EclipseME 600) thatwas ﬁttedwith
a camera (Micropublisher 3.3 RTV, 3.3 megapixel CCD Color-Bayer Mo-
saic, Real Time Viewing camera, Media Cybernetics, Marlow, UK). Parti-
cle morphology was further investigated utilizing the scanning electron
microscope (SEM, XL30 FEG, Philips). Average particle size and size dis-
tribution were obtained using Image J software, where 300 particles
were studied.
2.5.2. Transmission electron microscopy
Particles were collected on 400mesh copper TEM grids. TEM studies
were conducted at 120 kV (Philips CM 120 Bio-Twin) for the examina-
tion of different layer formation.
2.5.3. Focused ion beam (FIB) microscopy
Cross sectional images of the particles were prepared using focused
ion beam milling (FIB) (Carl Zeiss XB 1540 “Cross-Beam”) equipped
with a Gemini SEM column. Particles were gold sputtered for 120 s
and mounted on metallic studs. Accelerating voltage of 5 to 10 kV was
used during scanning.
2.5.4. Fourier transform infrared spectroscopy
Fourier transform infrared spectroscopy (FTIR)was performed using
a Spectrum 100 FTIR spectrometer (FTIR-ATR- PerkinElmer) ﬁtted with
an ATR attachment. Spectra of paracetamol, indomethacin, PLGA, PEG
and the prepared formulations were recorded using a frequency range
of 750–4000 cm−1 and a set resolution of 1 cm−1. Powdered samples
were positioned on the attenuated total reﬂectance (ATR) crystal and
compressed using an axial screw.
2.5.5. Differential scanning calorimetry
Differential Scanning Calorimetry (Netzsch STA 449C Jupiter, Netzch
USA) was used to observe the thermal behaviour of pure PLGA, PEG,
paracetamol and indomethacin as well as the prepared formulations in-
cluding unloaded particles, paracetamol loaded particles, indomethacin
loaded particles, and paracetamol and indomethacin loaded particles.
Table 4
Properties of the drug containing solutions used in this work.
Solution Surface tension (mN/m) Viscosity (mPa s) Electrical conductivity (μS/cm)
4% w/w PLGA in DMC 25.7 ± 0.16 1.97 ± 0.19 0.01 ± 0
4% w/w PLGA, 0.4% w/w Indomethacin in DMC 24.9 ± 0.15 1.9 ± 0.09 0.03 ± 0.02
2% w/w PEG in MeOH 22.8 ± 0.30 0.93 ± 0.05 22.3 ± 0.45
2% w/w PEG, 0.2% w/w Paracetamol in MeOH 23 ± 0.39 1.94 ± 0.07 23.8 ± 0.35
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temperature range of 30 °C to 200 °C at a rate of 5 °C/min.
2.5.6. Drug loading and entrapment efﬁciency
30 mg of drug-loaded microparticles were dissolved in
dimethylacetamide (DMAc) then diluted with PBS pH 7.4 and agitated
for 1 h under sealed conditions. The obtained solution was then ﬁltered
through 0.22 μm ﬁlters and the drug contentwas analysed using UV/VIS
Spectrometer (Cary 300 UV–Vis, Agilent Technologies) at correspond-
ing detection wavelengths (243 nm for paracetamol and 320 nm for in-
domethacin). Calibration curveswere also obtained in the range of 1–50
μg/ml where a good correlation was found over the covered range. The
drug loading and the drug entrapment efﬁciency were calculated using
the following equations, respectively:
Drug Loading %ð Þ ¼ Mactual=weighed amount of microparticlesð Þ
 100 ð2Þ
Encapsulation Efficiency %ð Þ ¼ Mactual=Mtheoreticalð Þ  100 ð3Þ
M indicates the mass of the drug.
2.5.7. In vitro drug release study
20 mg of micro-particles were placed in 50 ml of PBS pH 7.4 at a set
temperature of 37 °C ± 1. 3 ml of samples were taken at a
predetermined time interval for 8 h and ﬁltered using 0.22 μm ﬁlters
to ensure that no particles were collected at the point of withdrawing
aliquots. The samples were analysed using UV/Vis Spectrometer. Each
time 3 ml of PBS was added in order to maintain constant volume of
the dissolution medium.Fig. 1. Schematic diagram of co-axial electr3. Results and discussion
3.1. Jetting behaviour of polymeric solutions
In EHDA processing, physical properties of the ﬂowing solution in-
cluding viscosity, surface tension and electrical conductivity are of cru-
cial importance as they govern the jet and consequently the particle
formation [36]. In addition to these physical properties, careful selection
of processing parameters such asﬂow rate, applied voltage andworking
distance further controls the establishment of the stable cone-jet mode
[37]. The atomization mode could vary between cone-jet mode and
dripping mode based on the variation of electric ﬁeld strength, which
can be increased either by increasing the applied voltage or by decreas-
ing the working distance [38].
3.2. Polymeric drug delivery system
In this work, particles with and without the incorporation of model
drugs were made. In the case of unloaded polymeric particles, the
inner needle was infused with 2% w/w, 4% w/w and 6% w/w PEG in
methanol and the outer needle was infused with PLGA 4% w/w, 6% w/
w and 8% w/w in DMC. This was done prior to drug loading to optimize
the polymeric carrier system. The selected systemwas chosen based on
successful preparation of optimum particle size with narrow size distri-
bution and reproducible results that was achievable due to formation of
the stable cone jet. The inner and outer layer had nearly the same sur-
face tension; which in turn results in formation of ﬂowing mediums
that are treated as one [39].
The ﬂow rates of the inner and outer solution were set at 4 μl/min
and 10 μl/min for the ﬁrst polymeric solution system (S1) (Fig. 2a),
the higher acquired ﬂow rate for the outer solution was due to higherohydrodynamic atomization process.
Fig. 2. SEM images and size distribution graphs of particles made with a) S1 (2%w/w PEG, 4%w/w PLGA), b) S2 (4% w/w PEG, 6% w/w PLGA), c) S3 (6% w/w PEG, 8% w/w PLGA). The ﬁrst
mentioned is the inner layer.
Fig. 3. SEM images and particle size distribution histograms of a) PCMP, b) INDOP and c) PCMINDOP.
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electrical stresses toward the apex of the Taylor cone, while overcoming
the surface tension and thus establishing a stable cone-jet. The slight
difference in the polymer solution viscosities, as shown in Table 2, is
favourable to formation of compact particles in the co-axial
electrohydrodynamic atomization [40]. When compared to S2 and S3,
S1 has slightly higher mean particle size (8.06 μm ± 0.85) as a result
of higher ﬂow rate in the outer needle and lower applied voltage of
16.9 kV with respect to the other systems (Fig. 2a).
As for the other two systems, the ﬂow rate was set to 4 μl/min and 8
μl/min for the second system (S2) (Fig. 2b) and 4 μl/min and 8 μl/min for
the third system (S3) (Fig. 2c); with an applied voltage of 17.9 kV and
17.6 kV respectively, in order to achieve a stable cone jet that would re-
sult in formation of nearly monodispersed particles as seen in Figs. 2b
and c. The mean particle size for S2 and S3 were 6.74 μm ± 0.69 and
6.44 μm±0.86. It is also worth noting that theminimum required solu-
tion electrical conductivity is approximately≈ 0.01 μS/m for EHD pro-
cessing [40], which is met in this study as shown by Table 2.
Upon evaporation of solvents, microparticles are produced where
the evaporation rate of the selected solvents inﬂuence the particle size
distribution; the higher the evaporation rate and the lower the melting
point, the smaller the particles as there is successively a greater loss of
solvents as the cone-jet emits and lands on the collection platform.
The yield of the process was measured and a mean of 60–70% parti-
cle collection was achieved followed by optimization of the collection
platform.
3.3. Incorporation of the model drugs
With the addition of much more soluble drug (paracetamol) in the
inner layer theparticles formingparameters,ﬂowrate andapplied voltage
were adjusted in order to achieve the desired particle size while keepingFig. 4. TEMmicrographs of a) unloaded particles S1, b) PCMP, c) INDOP and d) PCMINDOP (with
ﬂow rates of 4 μl/min and 14 μl/min for PCMP and PCMINDOP, respectively).the working distance constant. The ﬂow rates of the inner and outer
layer were 4 μl/min, 14 μl/min at 15.7 kV (Fig. 3a) for the PCMP formula-
tion (Table 3). The mean particle size achieved was 5.3 μm± 0.6 with a
polydispersity of 10%. For preparation of INDOP formulation (Table 3),
the practically water insoluble model drug (indomethacin) was then
added to the system (Fig. 3b) and processed where the ﬂow rates of the
inner and outer layer were 4 μl/min, 10 μl/min at 16.4 kV. The mean
particle size achieved was 7.4 μm± 0.8 with a polydispersity of 10%.
Upon establishment of the drug delivery carriers incorporating a
single drug at a time, binary drug delivery systems were developed by
simultaneous incorporation of the two model drugs (Fig. 3c). Here, to
prepare PCMINDOP formulation (Table 3), the processing parameters
were set at 4 μl/min, 14 μl/min for the inner needle and outer needle
ﬂow rate, respectively, with an applied voltage of 15 kV, where a
mean particle size of 7.7 μm ± 0.8 with 10% polydispersity was
achieved. Themean particle sizewas lowest for PCMP,which is attribut-
able to higher surface tension of the outer needle solution (Table 4),
even though the applied voltage is lower of that of INDOP. In the
INDOP formulation, the ﬂow rate of the outer solution is set at a lower
value when compared with the other two formulations, this was due
to slightly higher conductivity of the outer solution that in turn resulted
in adaptation of a lower ﬂow rate [41].
From the TEM images obtained (Fig. 4) it can clearly be seen that the
prepared formulations exhibit a double-layer structure as distinguished
by the difference in contrast between the inner PEG and outer PLGA
layer. Yellow arrows and dotted lines indicate different layers as
shown in Fig. 4. It is evident that there is an overall size difference
from one layer to another that is attributable to the different ﬂow
rates used for each solution. It must be noted that varying the material
and processing parameters further modulates layer thickness. More-
over, the formation of a double-layered structure is preserved in all
formulations.inner and outerﬂow rates of 4 μl/min and 10 μl/min for S1 and INDOP, and inner and outer
Fig. 5. SEM/FIB cross-section images of unloadedparticles S1 (yellow arrows are indicative of the cross sectional cuts). (For interpretation of the references to color in thisﬁgure legend, the
reader is referred to the web version of this article.)
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the porosity of the prepared formulation were studied using FIB/SEM
(Fig. 5). The particles show a smooth surface indicating high solubility
of the polymers in the associated solvents used. The yellow arrows are
indicative of the cross sectional cuts through the microparticles.
FTIR spectra were recorded to investigate possible interaction be-
tween PLGA and PEG with the corresponding drugs indomethacin and
paracetamol during encapsulation. FTIR spectra of PLGA, PEG, indo-
methacin and paracetamol before and after undergoing processing are
also shown in Fig. 6.
The pure indomethacin sample demonstrates characteristic peaks at
1689 cm−1 (amide group) and 1721 cm−1 (carboxyl stretching), the
pure paracetamol exhibited O\\H stretching at 3100 cm−1 to
3500 cm−1, N\\H stretching at 3200 cm−1 to 3400 cm−1, and C_O
stretching from 1620 cm−1 to 1655 cm−1, also para-distributed aro-
matic ring from 750 cm−1 to 850 cm−1. Moreover, pure PEG showed
stretching C\\O from 1000 cm−1 to 1260 cm−1, stretching C\\O\\C
from 1050 cm−1 to 1150 cm−1, stretching C\\H from 1300 cm−1 to
1450 cm−1 and 2850 cm−1 to 2960 cm−1. From pure PLGA the bands
at 1050 cm−1 to 1250 cm−1 are characteristic of C\\O stretching of al-
iphatic polyesters and also at 1760 cm−1 C_O bond stretching was ob-
served. The drug loaded particles show combination of peaks
corresponding to polymers and model drugs showing there is no
degrading interaction between the components.
DSC measurements (Fig. 7) indicate the physical state of paraceta-
mol and indomethacin within the developed formulations (PCMP,
INDOP and PCMINDOP). The thermographs obtained for PLGA and
PEG indicates a glass transition temperature at 50 °C and 62 °C, respec-
tively. However, these endothermic peaks were absent in the preparedFig. 6. FTIR spectra of PLGA (50:50), PEG, unloaded partformulations. Paracetamol and indomethacin melting peaks in pure
form were observed at 170 °C and 160 °C, respectively. These peaks
were not identiﬁed in the prepared formulations, suggesting that the in-
corporated drugs were well integrated in an amorphous form, which
leads to development of the formulations that incorporated more
water soluble form of the model drugs. This is attributed to the nature
of EHDA process, whereby the polymeric system adopts a more amor-
phous state upon rapid evaporation of the solvent; hence the degree
of crystallinity of the drug is compromised. This is favourable in case
of encapsulation of drugs with low water solubility, resulting in higher
degree of dissolution when introduced as a solid oral dosage unit [24].3.4. Drug release
The encapsulation efﬁciency is a crucial parameter of the developed
microparticles and also an indicator of the efﬁciency of the co-axial
EHDA forming process [42]. The encapsulation efﬁciency of paracetamol
fromPCMP is 69% compared to that of PCMINDOP,which is 54%. The en-
capsulation efﬁciency of indomethacin in INDOP formulation is 78% and
is higher compared to that of PCMINDOP, which is 69%.
In general, drug release from biodegradable polymers occurs by sev-
eral mechanisms that couple and control the drug release rate [43]. In
matrix structures, drug release occursmainly through desorption of sur-
face bound drug, the diffusion of the drug through a polymeric matrix
and the polymer matrix erosion [43]. For particles of sub-micrometre
size, due to reduced size and increased surface area to volume ratio,
faster release of drug and higher degradation rate of the polymeric
system is facilitated [13].icles S1, INDOP, INDO, PCMP, PCM and PCMINDOP.
Fig. 7. DSC thermograms of PLGA (50:50), PEG, unloaded particles S1, paracetamol, indomethacin, PCMP, INDOP and PCMINDOP (endotherms are indicated as peaks).
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also PCMINDOP. As is suggested from Fig. 8, the release rate of paracet-
amol fromPCMINDOP is slower than that of PCMP. However, the release
pattern remained similar suggesting that drug dissolution occurred irre-
spective of the aqueous solubility of the drug. This is conﬁrmed by Du-
bois and Ford [44] who concluded that formulations containing low
drug concentration result in a polymer controlled dissolution proﬁle
that is predominantly dependent on the rate of dissolution of polymer
rather than the properties of the drug. In the paracetamol release proﬁle
from PCMP 59% of the drug is released within the ﬁrst 2 h. The corre-
sponding value for PCMINDOP is 48%. The slightly higher release rate
of paracetamol from the PCMP is attributed to the smaller particle size
of 5 μm compared to that of 7.4 μmwhich further decreased the diffu-
sion distance that the drug needs to travel in order to reach the dissolu-
tion medium.
In-vitro release proﬁles of indomethacin showed a small difference
in release rate and proﬁle between INDOP and PCMINDOP formulation
(see Fig. 9.). This proves that there is no signiﬁcant inﬂuence from incor-
poration of paracetamol into the polymeric drug delivery systems. The
developed drug delivery systems incorporating indomethacin, which
is a practically water insoluble drug, has signiﬁcantly increased the dis-
solution of the active ingredient compared to that of the free drug. This
is attributed to reduced particle size of the drug delivery carrier as pre-
viously discussed. Increased surface area to volume ratio of the particles
is highly desirable for development of these formulations. Moreover, asFig. 8. Release proﬁles of Pconﬁrmed by DSC results, the developed formulation incorporating in-
domethacin is in amorphous form,which further enhances the aqueous
solubility of crystalline indomethacin and is accountable to the
favourable nature of EHDA processing. The rate of oral absorption of
the drug is often governed by the dissolution rate which is a key deter-
minant of its oral bioavailability [45]. As it can be seen from the release
proﬁle obtained for INDOP and PCMINDOP in Fig. 9, micro-particles give
an initial burst release in the ﬁrst 2 h when introduced to the release
medium and 72% and 68% of indomethacin is discharged, respectively.
In comparison, there was only 14.8% release of free indomethacin after
2 h. After 3 h, the release rate of indomethacin from INDOP and
PCMINDOP is decreased and follows a plateau. The initial release can
also be attributed to the accumulation of the drug at the surface of the
microparticles, which can be explained by difference in the degree sol-
ubility of polymer and the conjugating drug in the solvent used for pro-
cessing. This consequently results in dislocation of the drug to a
superﬁcial level, as solvent evaporation takes place. The monomer
ratio of PLGA that is used in this study contains 50% lactic acid 50%
glycolic acid. Among other existing monomer ratios of this polymer,
PLGA (50:50) offers the highest hydrophilicity and undergoes degrada-
tion at a faster rate [33]. Moreover, the water-soluble PEG core further
enhances the hydration of the polymermatrix [46]. As thewater perme-
ates inside the drug carriers, it hydrolyses the polymer and subsequent-
ly creates a pathway for the drug to be released by diffusion and erosion
until complete polymer solubilisation is achieved [33].CMP and PCMINDOP.
Fig. 9. Release proﬁles of indomethacin from free drug, INDOP and PCMINDOP.
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In thiswork, co-axial EHDAwas used to prepare a series of core-shell
polymeric systems. These comprised of using biodegradable biocompat-
ible polymers and incorporation of drugswith different aqueous solubil-
ity. Successful formation of core/shell particles was achieved. The
developed formulations offered enhanced release of thewater insoluble
drug (indomethacin), while controlling the release of the more highly
water-soluble drug (paracetamol). The co-axial EHDA processing of-
fered high processing yield of 70% with encapsulation efﬁciencies rang-
ing between 54% and 78%. The initial burst release, during the ﬁrst 2 h,
ranged between 48% and 72%. The simultaneous release proﬁles of the
model drugs satisfy the requirements of ﬁxed dose combination prod-
ucts where active pharmaceutical ingredients are incorporated into
the formulation for oral drug delivery systems.
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